Company: ATMCW
Filing Date: 2025-11-17
Form Type: DEFM14A
Source: 0001493152-25-023842
Chunk: 10

Company: ALPHATIME ACQUISITION CORP
Filing Date: 2025-11-17
Form: DEFM14A
Chunk 10
---
 HCYC HK is used to operate HCYC HK. At the close of this offering, the funds can be directly transferred to the operating subsidiary. At present, HCYC have never distributed any dividends and does not intend to in the future. However, if HCYC decides to distribute dividends to its shareholders, it will transfer the dividends from the operating subsidiary, HCYC HK, in accordance with the laws and regulations of Hong Kong and other countries. Then HCYC HK will transfer the dividends to HCYC, and the dividends will be distributed from HCYC to all shareholders respectively in proportion to the shares they hold, regardless of whether the shareholders are U.S. investors or investors in other countries or regions.

As a smaller company, HCYC does not have specific cash management policies and procedures that dictate how funds are transferred throughout the organization. HCYC’s general policy, however, has been to keep funds within the entities where they are raised or generated in order to support the local entity’s operations. For example, if the funds are generated in a Hong Kong subsidiary, then HCYC’s general approach will be to use those funds to support the Hong Kong entity’s operations, with the exception of required funding for capital investments. HCYC does not have any contractual agreements in place its operating subsidiary that establishes control over it. HCYC controls its operating subsidiary by virtue of holding all of the voting interest.

As of the date of this prospectus, no transfers, dividends, or distributions have been made between HCYC and HCYC HK. Further, no transfers, dividends, or distributions have been made to investors. Please see our Consolidated Financial Statementsstarting on page F-1.

Proposals to approve the Merger Agreement and the other matters discussed in this proxy statement/prospectus shall be presented at the Extraordinary General Meeting scheduled to be held on December 5, 2025.

This proxy statement/prospectus provides you with detailed information about the Business Combination and other matters to be considered at the Extraordinary General Meeting of AlphaTime Shareholders. We encourage you to carefully read this entire document. You should, in particular, carefully consider the risk factors described in “Risk Factors” beginning on page of this proxy statement/prospectus.

This proxy statement/prospectus is dated November 14, 2025 and is first being mailed to AlphaTime Shareholders on or about November 14, 2025.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE